|drug1513||Human umbilical cord derived CD362 enriched MSCs Wiki||1.00|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.09|
|D055371||Acute Lung Injury NIH||0.09|
There is one clinical trial.
Acute Respiratory Distress Syndrome (ARDS) causes the lungs to fail due to the collection of fluid in the lungs (pulmonary oedema). ARDS is common in severely ill patients in Intensive Care Units and is associated with a high mortality and a high morbidity in those who survive. ARDS occurs in approximately 20% case of COVID-19 and respiratory failure is the leading cause of mortality. There is a large economic burden with direct healthcare costs, but also indirectly due to the impact on the carer and patient through the patients inability to return to full time employment. There is little evidence for effective drug (pharmacological) treatment for ARDS. There is increasing information that mesenchymal stem cells (MSCs) might be important in treating ARDS. REALIST will investigate if a single infusion of MSCs will help in the treatment of ARDS. The first step will be to first of all determine what dose of MSCs is safe and then divide patients suffering from ARDS into two groups, one of which will get MSCs and the other a harmless dummy (or placebo) infusion, who will then be followed up to determine if lung function improves. If effective this may lead to further research to determine if MSCs are effective in patients with ARDS.
Description: OI is a physiological index of the severity of ARDS and measures both impaired oxygenation and the amount of mechanical ventilation deliveredMeasure: Oxygenation index (OI) Time: Day 7
Description: Incidence of SAEsMeasure: Incidence of Serious Adverse Events (SAEs) Time: 28 days
Description: SOFA score is a measure of organ failureMeasure: Sequential Organ Failure Assessment (SOFA) score Time: Days 4, 7 and 14
Description: Crs is a physiological measure of pulmonary function in ARDSMeasure: Respiratory compliance (Crs) Time: Days 4, 7 and 14
Description: P/F ratio is a physiological measure of pulmonary function in ARDSMeasure: Partial pressure of arterial oxygen to the fraction of inspired oxygen ratio (P/F ratio) Time: Days 4, 7 and 14
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports